Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Link
http://link.springer.com/content/pdf/10.1007/s10067-014-2744-6.pdf
Reference29 articles.
1. Atteno M, Peluso R, Costa L et al (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheum 29(4):399–403
2. Gorman J, Sack K, Davis J (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor (alpha). N Engl J Med 346(18):1349–1356
3. Mease P, Kivitz A, Burch F, Siegel E et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272
4. Mease P, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou C (2010) Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 37(6):1221–1227
5. Wanke LA, Mease P, Gottlieb A, Burge D (2004) Sustained improvement in activities of daily living and vitality in patients with psoriatic arthritis treated with etanercept. J Am Acad Derm 50(3):145
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Adalimumab or etanercept as first line biologic therapy in enthesitis related arthritis (ERA) - a drug-survival single centre study spanning 10 years;Seminars in Arthritis and Rheumatism;2022-08
2. Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast Asia;Expert Opinion on Biological Therapy;2022-07-27
3. Adalimumab Superior to Etanercept as First Line Biologic in ERA- a Drug Survival Single Centre Study Spanning 10 Years;SSRN Electronic Journal;2022
4. Juvenile Idiopathic Arthritis Treatment Updates;Rheumatic Disease Clinics of North America;2021-11
5. Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use;Rheumatology;2021-09-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3